Management | THE "NEW" PROSTATE CANCER INFOLINK

Recent lecture on the management of castration-resistant prostate cancer

Posted on April 10, 2013 by Sitemaster

The UroToday web site has just posted a detailed report on a presentation by Stephen Freedland, MD, of Duke University, given at the South East Section meeting of the American Urological Association in Williamsburg, VA, last month. This report will likely be of interest to patients with progressive forms of prostate cancer and many support group leaders. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, CRPC, Management | 5 Comments »

ASCO’s new CancerLinQ initiative

Posted on March 29, 2013 by Sitemaster

As we move near to the annual meeting of the American Society of Clinical Oncology (ASCO) — which will start at the end of May in Chicago – ASCO has been making a lot of noise about its prototype CancerLinQ™ network. Just how valuable this will be for the future management of prostate cancer will take a while to work out. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CancerLinQ, clinical, data, Management, outcomes, practise | 4 Comments »

Lots of new tests, but will they really make a difference?

Posted on March 26, 2013 by Sitemaster

An article by Andrew Pollack in Tuesday’s New York Times is entitled “New prostate cancer tests could reduce false alarms.” However, we encourage our readers to scrutinize this article with care. It is full of “may”s, “could”s, “might”s, and “if”s (as one should expect). … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, Management, prognosis, test | 1 Comment »

Managing the side effects of ADT — a new review

Posted on February 27, 2013 by Sitemaster

According to a new analysis and review of recent, published data, the “numerous well recognized adverse effects” of androgen deprivation therapy (ADT) include “vasomotor flushing, loss of libido and impotence, fatigue, gynecomastia, anemia, osteoporosis and metabolic complications, as well as effects on cardiovascular health and bone density.” … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: ADT, androgen, deprivation, Management, side effects | 6 Comments »

Active surveillance as a management strategy for younger men with low-risk disease

Posted on February 27, 2013 by Sitemaster

So a new paper just published on line in BJU International has (finally) provided some data to support a perspective that The “New” Prostate Cancer InfoLink has believed in for a considerable period of time … that active surveillance is a perfectly reasonable option for a high proportion of patients with low-risk prostate cancer who are ≤ 55 years of age. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, Management, risk, young | 9 Comments »

Dr. Peter Scardino on “screening” for risk of prostate cancer

Posted on December 13, 2012 by Sitemaster

There is an interesting piece just posted on the UroToday web site in which Dr. Peter Scardino (the Chief of Surgery at the Memorial Sloan-Kettering Cancer Center in New York, and the surgeon whose outcome data were used to develop the early versions of the Kattan nomograms) talks about appropriate modern attitudes to “screening” for prostate cancer. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, Management, PSA, risk, screening, testing | 9 Comments »

Active surveillance, deferred treatment, and outcomes among a Swedish patient cohort

Posted on October 9, 2012 by Sitemaster

Based on an average (median) follow-up of 6.0 years from diagnosis, nearly half of all men diagnosed in the Göteborg (Swedish) cohort of the European Randomized Study of Screening for Prostate Cancer (ERSCP) and managed with active surveillance have have been successfully managed without further intervention to date. … Only 9 percent of the patients actually showed clear signs of disease progression during the follow-up period. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surveillance, Management, risk, screening | 2 Comments »

Improving the quality of care for men with early stage prostate cancer

Posted on August 17, 2012 by Sitemaster

It is sometimes very irritating that good and thoughtful articles appearing in the professional journals are not easily accessible to a wider lay readership. An editorial by Behfar Ehdaie, MD, in the September issue of the Journal of Urology offers a case in point. … READ MORE …

Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, expectant, localized, Management, Treatment | Leave a Comment »

Active surveillance in the “real world” of clinical practice today

Posted on May 27, 2012 by Sitemaster

A poster to be presented at the upcoming ASCO annual meeting gives us some insights into the actual behaviors of physicians and their patients regarding the use of active surveillance today in the “real world” of clinical practice (as opposed to clinical trials and case series at academic medical centers). … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: active surveillance, low risk, Management | 6 Comments »

All the PIVOT trial hype from Europe

Posted on April 30, 2012 by Sitemaster

There has been a lot of media hype in Europe around the re-presentation of the PIVOT data by Dr. Wilt at the annual meeting of the European Association of Urology in Paris last week. And yet every prostate cancer specialist attending that meeting must have already been well aware of these data. … READ MORE …

Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Management, obseration, PIVOT, risk, surgery, surveillance, Treatment | 8 Comments »

The Berkshire Hathaway effect on prostate cancer management

Posted on April 18, 2012 by Sitemaster

As many readers will be aware, the Sage of Omaha, Warren Buffett, chairman and CEO of Berkshire Hathaway, announced yesterday that he has been diagnosed with prostate cancer that is “not remotely life threatening.” He does intend, however, to undergo 8 weeks of radiation therapy. Mr. Buffet is 81 years of age. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Buffett, Diagnosis, Management, risk | 6 Comments »

Increasing focus on the appropriate definition (and management) of prostate “cancer”

Posted on January 14, 2012 by Sitemaster

As many readers will be aware, there has been a recent and increasing focus on whether abnormal pathological findings on biopsy classified as Gleason grade 3 + 3 = 6 should really be classified as “cancer” at all. This also has major implications for its management. … READ MORE …

Filed under: Diagnosis, Management, Risk | Tagged: description, ethics, low risk, Management, Treatment | 14 Comments »

The new NCCN patient guidelines — a great improvement over last time

Posted on December 26, 2011 by Sitemaster

We have now had the chance to look carefully through the new, patient-specific guidelines on prostate cancer issued by the National Comprehensive Cancer Network (NCCN) just before the Holidays. They are not perfect, but they are certainly a vast improvement over the NCCN’s first attempt. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, guideline, Management, NCCN, patient, risk | 16 Comments »

Risk stratification in diagnosis and management of prostate cancer

Posted on November 28, 2011 by Sitemaster

A new article by Vickers, Roobol, and Lilja, scheduled for publication in the January 2012 issue of the Annual Review of Medicine is likely to raise some eyebrows in the urology community. … READ MORE …

Filed under: Diagnosis, Management, Risk | Tagged: Management, risk, sc reening, stratification | 7 Comments »

Aging, demography, and the long-term risk for prostate cancer

Posted on November 18, 2011 by Sitemaster

A new report from the census bureau indicates that there is (as one might have expected) a rapid growth in the number of people in the US who are now living to 90+ years of age. It is also reasonable to expect that this demographic change has implications for the diagnosis and risk for prostate cancer among such older males. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: aging, demography, Management, risk | 2 Comments »

THE "NEW" PROSTATE CANCER INFOLINK

Other PCI web sites